Observes how lung cancer is diagnosed and treated in routine care
Collects real-world records on lung cancer testing, treatment and disease progression in adults.
Plain-language title generated from the registry record
Registry title: LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Key facts
- Where
- Vienna, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 125 years old?
Source: NCT04733430, who can take part
Where in Austria
- Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische OnkologieVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology
- Trial code
- NCT04733430
- Record updated
- 18 March 2024
- Original description
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.Read full original descriptionShow less
Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.
Inclusion: Informed consent; Histologically confirmed lung cancer; Age ≥ 18 years; Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments.
Exclusion: -.